NCT03668847
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Chemotherapy
Key Eligibility Criteria:
Gender: All
Age: 15 Years to 39 Years (Child, Adult)
Location of Metastases: Brain
Additional Notes:
Exclusions:
https://ClinicalTrials.gov/show/NCT03668847